271 related articles for article (PubMed ID: 36396085)
1. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
Zheng Q; Wang Y; Yang H; Sun L; Zhang P; Zhang X; Guo J; Liu YN; Liu WJ
Am J Kidney Dis; 2023 Apr; 81(4):434-445.e1. PubMed ID: 36396085
[TBL] [Abstract][Full Text] [Related]
2. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
3. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
4. Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis.
Guimarães MGM; Tapioca FPM; Neves FC; Moura-Neto JA; Passos LCS
Blood Purif; 2023; 52(7-8):721-728. PubMed ID: 37459846
[TBL] [Abstract][Full Text] [Related]
5. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis.
Chen D; Niu Y; Liu F; Yang Y; Wang X; Li P; Chen X
Front Pharmacol; 2023; 14():1163908. PubMed ID: 37292157
[No Abstract] [Full Text] [Related]
6. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
7. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis.
Zheng Q; Zhang P; Yang H; Geng Y; Tang J; Kang Y; Qi A; Li S
Heliyon; 2023 Apr; 9(4):e15310. PubMed ID: 37123954
[TBL] [Abstract][Full Text] [Related]
8. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Li J; Xie QH; You L; Xu NX; Hao CM
Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
10. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
11. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
Zhao H; Li P; Zhang HL; Jia L
Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
Tian L; Wang M; Liu M; Pang Y; Zhao J; Zheng B; Wang Y; Zhao W
Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.
Natale P; Palmer SC; Jaure A; Hodson EM; Ruospo M; Cooper TE; Hahn D; Saglimbene VM; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD013751. PubMed ID: 36005278
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials.
Minutolo R; Liberti ME; Simeon V; Sasso FC; Borrelli S; De Nicola L; Garofalo C
Clin Kidney J; 2024 Jan; 17(1):sfad143. PubMed ID: 38186871
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
19. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
